salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life唾液的关于7价肺炎球菌结合疫苗免疫反应的前2年的生活.pdfVIP

Salivary Immune Responses to the 7-Valent Pneumococcal Conjugate Vaccine in the First 2 Years of Life 1 1 1,2 2 Gerwin D. Rodenburg , Elisabeth A. M. Sanders , Elske J. M. van Gils , Reinier H. Veenhoven , 1 3 4 3 Tomasz Zborowski , Germie P. J. M. van den Dobbelsteen , Andries C. Bloem , Guy A. M. Berbers , Debby Bogaert1* 1 Department of Pediatric Immunology and Infectious Diseases, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands, 2 Linneaus Institute, Spaarne Hospital, Hoofddorp, The Netherlands, 3 National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 4 Department of Immunology, University Medical Center Utrecht, Utrecht, The Netherlands Abstract Background: The CRM197-conjugated 7-valent pneumococcal vaccine (PCV7) is protective against vaccine serotype disease and nasopharyngeal carriage. Data on PCV7-induced mucosal antibodies in relation to systemic or natural anticapsular antibodies are scarce. Methods: In a randomized controlled setting, children received PCV7 at age 2 and 4 months (2-dose group), at age 2, 4 and 11 months (2+ 1-dose group) or no PCV7 (control group). From 188 children paired saliva samples were collected at 12 and 24 months of age. From a subgroup of 15 immunized children also serum samples were collected. IgG and IgA antibody- levels were measured by multiplex immunoassay. Results: At 12 months, both vaccine groups showed higher serum and saliva IgG-levels against vaccine serotypes compared with controls which sustained until 24 months